Review



xbp1s  (Cell Signaling Technology Inc)


Bioz Verified Symbol Cell Signaling Technology Inc is a verified supplier
Bioz Manufacturer Symbol Cell Signaling Technology Inc manufactures this product  
  • Logo
  • About
  • News
  • Press Release
  • Team
  • Advisors
  • Partners
  • Contact
  • Bioz Stars
  • Bioz vStars
    • 86
      Buy from Supplier

    Structured Review

    Cell Signaling Technology Inc xbp1s
    Sch B induced a dose-dependent increase in ROS levels in CCA cells. (A) BIP, (B) CHOP and (C) <t>XBP1s</t> expressions were determined by reverse-transcription quantitative PCR in CCA cells treated with different concentrations of Sch B (0, 10, 20, 40, 80, 160 µmol/l), (D) BIP, CHOP and XBP1s expression levels were determined by western blotting in CCA cells treated with different concentrations of Sch B (0, 40, 80, 160 µmol/l). (E) ROS levels in CCA cells treated with different concentrations of Sch B (0, 40, 80, 160 µmol/l) were measured using the ROS probe DCFH-DA. (F) Flow cytometry analysis of ROS levels in CCA cells following treatment with various Sch B concentrations (0, 40, 160 µmol/l). Statistical analysis was performed using ANOVA and Dunnett's post hoc test. *P<0.05, **P<0.01, ***P<0.001. CCA, cholangiocarcinoma; Sch B, Schisandrin B; Ctrl, control; ROS, reactive oxygen species.
    Xbp1s, supplied by Cell Signaling Technology Inc, used in various techniques. Bioz Stars score: 86/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
    https://www.bioz.com/product/xbp1s/pmc13051282-3-0-6
    Average 86 stars, based on 1 article reviews
    xbp1s - by Bioz Stars, 2026-09
    86/100 stars

    Images

    1) Product Images from "Schisandrin B suppresses cholangiocarcinoma by targeting the ROS/p38 MAPK/NF-κB axis"

    Article Title: Schisandrin B suppresses cholangiocarcinoma by targeting the ROS/p38 MAPK/NF-κB axis

    Journal: Oncology Letters

    doi: 10.3892/ol.2026.15551

    Sch B induced a dose-dependent increase in ROS levels in CCA cells. (A) BIP, (B) CHOP and (C) XBP1s expressions were determined by reverse-transcription quantitative PCR in CCA cells treated with different concentrations of Sch B (0, 10, 20, 40, 80, 160 µmol/l), (D) BIP, CHOP and XBP1s expression levels were determined by western blotting in CCA cells treated with different concentrations of Sch B (0, 40, 80, 160 µmol/l). (E) ROS levels in CCA cells treated with different concentrations of Sch B (0, 40, 80, 160 µmol/l) were measured using the ROS probe DCFH-DA. (F) Flow cytometry analysis of ROS levels in CCA cells following treatment with various Sch B concentrations (0, 40, 160 µmol/l). Statistical analysis was performed using ANOVA and Dunnett's post hoc test. *P<0.05, **P<0.01, ***P<0.001. CCA, cholangiocarcinoma; Sch B, Schisandrin B; Ctrl, control; ROS, reactive oxygen species.
    Figure Legend Snippet: Sch B induced a dose-dependent increase in ROS levels in CCA cells. (A) BIP, (B) CHOP and (C) XBP1s expressions were determined by reverse-transcription quantitative PCR in CCA cells treated with different concentrations of Sch B (0, 10, 20, 40, 80, 160 µmol/l), (D) BIP, CHOP and XBP1s expression levels were determined by western blotting in CCA cells treated with different concentrations of Sch B (0, 40, 80, 160 µmol/l). (E) ROS levels in CCA cells treated with different concentrations of Sch B (0, 40, 80, 160 µmol/l) were measured using the ROS probe DCFH-DA. (F) Flow cytometry analysis of ROS levels in CCA cells following treatment with various Sch B concentrations (0, 40, 160 µmol/l). Statistical analysis was performed using ANOVA and Dunnett's post hoc test. *P<0.05, **P<0.01, ***P<0.001. CCA, cholangiocarcinoma; Sch B, Schisandrin B; Ctrl, control; ROS, reactive oxygen species.

    Techniques Used: Reverse Transcription, Real-time Polymerase Chain Reaction, Expressing, Western Blot, Flow Cytometry, Control

    NAC counteracted the upregulatory effect of Sch B on ROS expression. After treatment with 160 µmol/l Sch B + different concentrations of NAC (0, 0.5, 1, 3, 6 µmol/l). BIP, CHOP and XBP1s expression determined by (A) western blotting and (B) reverse transcription-quantitative PCR in CCA cells. (C) LDH activity in cell culture medium. (D) Cell activity levels detected by the Calcein AM-PI live cell staining. (E) Western blot analysis of the expression levels of Bax in CCA cells. Statistical analysis was performed using ANOVA and Dunnett's post hoc test. **P<0.01, ***P<0.001. ROS, reactive oxygen species; CCA, cholangiocarcinoma; NAC, N-acetyl-L-cysteine; ctrl, control; Sch B, Schisandrin B; LDH, lactate dehydrogenase.
    Figure Legend Snippet: NAC counteracted the upregulatory effect of Sch B on ROS expression. After treatment with 160 µmol/l Sch B + different concentrations of NAC (0, 0.5, 1, 3, 6 µmol/l). BIP, CHOP and XBP1s expression determined by (A) western blotting and (B) reverse transcription-quantitative PCR in CCA cells. (C) LDH activity in cell culture medium. (D) Cell activity levels detected by the Calcein AM-PI live cell staining. (E) Western blot analysis of the expression levels of Bax in CCA cells. Statistical analysis was performed using ANOVA and Dunnett's post hoc test. **P<0.01, ***P<0.001. ROS, reactive oxygen species; CCA, cholangiocarcinoma; NAC, N-acetyl-L-cysteine; ctrl, control; Sch B, Schisandrin B; LDH, lactate dehydrogenase.

    Techniques Used: Expressing, Western Blot, Reverse Transcription, Real-time Polymerase Chain Reaction, Activity Assay, Cell Culture, Staining, Control

    Related Articles

    other:

    Article Title: Schisandrin B suppresses cholangiocarcinoma by targeting the ROS/p38 MAPK/NF-κB axis
    Article Snippet: XBP1s , 12782 , 1:1,000 , Cell Signaling Technology, Inc..

    Article Title: Schisandrin B suppresses cholangiocarcinoma by targeting the ROS/p38 MAPK/NF‑κB axis
    Article Snippet: Antibody name Cat. no. Dilution Supplier Primary antibodies BIP 3183 1:1,000 Cell Signaling Technology, Inc. CHOP 2895 1:1,000 Cell Signaling Technology, Inc. XBP1s 12782 1:1,000 Cell Signaling Technology, Inc. Bax 5023 1:1,000 Cell Signaling Technology, Inc. p‐p38 MAPK (Thr180/Tyr182) 4511 1:1,000 Cell Signaling Technology, Inc. p38 MAPK 8690 1:1,000 Cell Signaling Technology, Inc. p‐p65 NF‐κB (Ser536) 3033 1:1,000 Cell Signaling Technology, Inc. p65 NF‐κB 8242 1:1,000 Cell Signaling Technology, Inc. p‐IκBα (Ser32) 2859 1:1,000 Cell Signaling Technology, Inc. IκBα 4814 1:1,000 Cell Signaling Technology, Inc. IL‐6 12153 1:1,000 Cell Signaling Technology, Inc. IL‐8 94407 1:1,000 Cell Signaling Technology, Inc. TNF‐α 6945 1:1,000 Cell Signaling Technology, Inc. GAPDH 5174 1:5,000 Cell Signaling Technology, Inc.

    Ubiquitin Proteomics:

    Article Title: Alcohol Consumption During Muscle Disuse Causes Differential Signaling Responses in a Muscle-Specific Manner in Mice
    Article Snippet: .. The primary antibodies were directed against antibodies p-mTOR (S2448, #2971, 1:1000), mTOR (#2983, 1:1000), p-Akt (Ser473, #9271, 1:1000), Akt (#9272, 1:1000), p-p70S6K (T389, #9234, 1:1000), p70S6K (#2708, 1:1000), p-4EBP1 (Thr37/46, #2855, 1:1000), 4EBP1 (#9644, 1:1000), ubiquitin (#8395, 1:1000), p-PERK (Thr980, #3179, 1:1000), PERK (#5683, 1:1000), ATF6 (#65880S, 1:1000), BIP (#3177, 1:1000), ATF4 (#11815, 1:1000), XBP1s (#40435, 1:1000), p-eIF2α (#3398, 1:1000), eIF2α (#9722, 1:1000), and CHOP (#2895, 1:1000) were purchased from Cell Signaling Technology (Danvers, MA, USA). .. MuRF1 (sc-398608, 1:1000), MAFbx (sc-166806, 1:1000), and LC3-I/II (sc-376404, 1:1000) were purchased from Santa Cruz Biotechnology, Inc. (Dallas, TX, USA).

    Article Title: Alcohol Consumption During Muscle Disuse Causes Differential Signaling Responses in a Muscle-Specific Manner in Mice
    Article Snippet: .. The primary antibodies were directed against antibodies p-mTOR (S2448, #2971, 1:1000), mTOR (#2983, 1:1000), p-Akt (Ser473, #9271, 1:1000), Akt (#9272, 1:1000), p-p70S6K (T389, #9234, 1:1000), p70S6K (#2708, 1:1000), p-4EBP1 (Thr37/46, #2855, 1:1000), 4EBP1 (#9644, 1:1000), ubiquitin (#8395, 1:1000), p-PERK (Thr980, #3179, 1:1000), PERK (#5683, 1:1000), ATF6 (#65880S, 1:1000), BIP (#3177, 1:1000), ATF4 (#11815, 1:1000), XBP1s (#40435, 1:1000), p-eIF2α (#3398, 1:1000), eIF2α (#9722, 1:1000), and CHOP (#2895, 1:1000) were purchased from Cell Signaling Technology (Danvers, MA, USA). .. MuRF1 (sc-398608, 1:1000), MAFbx (sc-166806, 1:1000), and LC3-I/II (sc-376404, 1:1000) were purchased from Santa Cruz Biotechnology, Inc. (Dallas, TX, USA).



    Similar Products

    xbp1s inhibitor  (MedChemExpress)
    94
    MedChemExpress xbp1s inhibitor
    IL22 upregulates PD-L1 expression in gastric cancer cells through the UPR IRE1α–XBP1 axis. A, mIF images show the alterations of PD-L1 + tumor cells (purple), CD4 + (green), and CD8 + (red) T cells in orthotopic gastric cancer tumors from control and Abhd16a -knockdown mice following IL22 treatment. Scale bar, 50 μm. B, KEGG pathway enrichment analysis of RNA-seq data of gastric cancer tissues with or without IL22 treatment. C, RT-PCR was used to assess the mRNA expression of key downstream molecules of the UPR branches ( XBP1 , ATF4 , ATF6 ) in control and IL22RA1 -knockdown gastric cancer cells. D, Western blotting analysis of PD-L1 and <t>XBP1s</t> levels in control and IL22RA1 -knockdown MGC-803 cells treated with IL22 (100 μg/L). E, Western blotting detection of PD-L1 and XBP1s levels in XBP1- knockdown MGC-803 cells treated with IL22 and MGC-803 cells treated with IL22 or XBP1s inhibitor (STF083010, 30 μmol/L) in combination with IL22. F, The binding sequence of XBP1 on the CD274 promoter. G and H, ChIP ( G ) and luciferase reporter assay ( H ) showing the transcriptional regulation of CD274 by XBP1s under IL22 stimulation. I, Orthotopic gastric cancer mouse models ( n = 5 per group) were injected with anti-IL22 (200 μg per mouse), anti-CD90.2 antibody (150 μg per mouse), anti-CD90.2 antibody in combination with IL22 (500 ng per mouse), or anti-CD90.2 antibody in combination with XBP1s inhibitors (STF083010, 30 mg/kg) and IL22 for 2 weeks. IHC analysis was used to show IL22, XBP1s, and PD-L1 levels in gastric cancer tissues. Scale bar, 200 μm. J, Tumor volume of orthotopic gastric cancer models under treatments the same as in I . *, P < 0.05; **, P < 0.01; ***, P < 0.001; ns, nonsignificant.
    Xbp1s Inhibitor, supplied by MedChemExpress, used in various techniques. Bioz Stars score: 94/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
    https://www.bioz.com/product/xbp1s/Perifosine/pmc13080324-119-26-31
    Average 94 stars, based on 1 article reviews
    xbp1s inhibitor - by Bioz Stars, 2026-09
    94/100 stars
    		  Buy from Supplier
    liver specific xbp1 ablation  (Henkel Corporation)
    86
    Henkel Corporation liver specific xbp1 ablation
    IL22 upregulates PD-L1 expression in gastric cancer cells through the UPR IRE1α–XBP1 axis. A, mIF images show the alterations of PD-L1 + tumor cells (purple), CD4 + (green), and CD8 + (red) T cells in orthotopic gastric cancer tumors from control and Abhd16a -knockdown mice following IL22 treatment. Scale bar, 50 μm. B, KEGG pathway enrichment analysis of RNA-seq data of gastric cancer tissues with or without IL22 treatment. C, RT-PCR was used to assess the mRNA expression of key downstream molecules of the UPR branches ( XBP1 , ATF4 , ATF6 ) in control and IL22RA1 -knockdown gastric cancer cells. D, Western blotting analysis of PD-L1 and <t>XBP1s</t> levels in control and IL22RA1 -knockdown MGC-803 cells treated with IL22 (100 μg/L). E, Western blotting detection of PD-L1 and XBP1s levels in XBP1- knockdown MGC-803 cells treated with IL22 and MGC-803 cells treated with IL22 or XBP1s inhibitor (STF083010, 30 μmol/L) in combination with IL22. F, The binding sequence of XBP1 on the CD274 promoter. G and H, ChIP ( G ) and luciferase reporter assay ( H ) showing the transcriptional regulation of CD274 by XBP1s under IL22 stimulation. I, Orthotopic gastric cancer mouse models ( n = 5 per group) were injected with anti-IL22 (200 μg per mouse), anti-CD90.2 antibody (150 μg per mouse), anti-CD90.2 antibody in combination with IL22 (500 ng per mouse), or anti-CD90.2 antibody in combination with XBP1s inhibitors (STF083010, 30 mg/kg) and IL22 for 2 weeks. IHC analysis was used to show IL22, XBP1s, and PD-L1 levels in gastric cancer tissues. Scale bar, 200 μm. J, Tumor volume of orthotopic gastric cancer models under treatments the same as in I . *, P < 0.05; **, P < 0.01; ***, P < 0.001; ns, nonsignificant.
    Liver Specific Xbp1 Ablation, supplied by Henkel Corporation, used in various techniques. Bioz Stars score: 86/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
    https://www.bioz.com/product/xbp1s/ablation+liver+specific+xbp1/pm42302643-46-0-20
    Average 86 stars, based on 1 article reviews
    liver specific xbp1 ablation - by Bioz Stars, 2026-09
    86/100 stars
    		  Buy from Supplier
    anti xbp1  (Affinity Biosciences)
    86
    Affinity Biosciences anti xbp1
    IL22 upregulates PD-L1 expression in gastric cancer cells through the UPR IRE1α–XBP1 axis. A, mIF images show the alterations of PD-L1 + tumor cells (purple), CD4 + (green), and CD8 + (red) T cells in orthotopic gastric cancer tumors from control and Abhd16a -knockdown mice following IL22 treatment. Scale bar, 50 μm. B, KEGG pathway enrichment analysis of RNA-seq data of gastric cancer tissues with or without IL22 treatment. C, RT-PCR was used to assess the mRNA expression of key downstream molecules of the UPR branches ( XBP1 , ATF4 , ATF6 ) in control and IL22RA1 -knockdown gastric cancer cells. D, Western blotting analysis of PD-L1 and <t>XBP1s</t> levels in control and IL22RA1 -knockdown MGC-803 cells treated with IL22 (100 μg/L). E, Western blotting detection of PD-L1 and XBP1s levels in XBP1- knockdown MGC-803 cells treated with IL22 and MGC-803 cells treated with IL22 or XBP1s inhibitor (STF083010, 30 μmol/L) in combination with IL22. F, The binding sequence of XBP1 on the CD274 promoter. G and H, ChIP ( G ) and luciferase reporter assay ( H ) showing the transcriptional regulation of CD274 by XBP1s under IL22 stimulation. I, Orthotopic gastric cancer mouse models ( n = 5 per group) were injected with anti-IL22 (200 μg per mouse), anti-CD90.2 antibody (150 μg per mouse), anti-CD90.2 antibody in combination with IL22 (500 ng per mouse), or anti-CD90.2 antibody in combination with XBP1s inhibitors (STF083010, 30 mg/kg) and IL22 for 2 weeks. IHC analysis was used to show IL22, XBP1s, and PD-L1 levels in gastric cancer tissues. Scale bar, 200 μm. J, Tumor volume of orthotopic gastric cancer models under treatments the same as in I . *, P < 0.05; **, P < 0.01; ***, P < 0.001; ns, nonsignificant.
    Anti Xbp1, supplied by Affinity Biosciences, used in various techniques. Bioz Stars score: 86/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
    https://www.bioz.com/product/xbp1s/antibody+primary+xbp1/pmc13275982-110-0-1
    Average 86 stars, based on 1 article reviews
    anti xbp1 - by Bioz Stars, 2026-09
    86/100 stars
    		  Buy from Supplier
    genomics xbp1s mouse fwd  (Eurofins Genomics)
    86
    Eurofins Genomics genomics xbp1s mouse fwd
    IL22 upregulates PD-L1 expression in gastric cancer cells through the UPR IRE1α–XBP1 axis. A, mIF images show the alterations of PD-L1 + tumor cells (purple), CD4 + (green), and CD8 + (red) T cells in orthotopic gastric cancer tumors from control and Abhd16a -knockdown mice following IL22 treatment. Scale bar, 50 μm. B, KEGG pathway enrichment analysis of RNA-seq data of gastric cancer tissues with or without IL22 treatment. C, RT-PCR was used to assess the mRNA expression of key downstream molecules of the UPR branches ( XBP1 , ATF4 , ATF6 ) in control and IL22RA1 -knockdown gastric cancer cells. D, Western blotting analysis of PD-L1 and <t>XBP1s</t> levels in control and IL22RA1 -knockdown MGC-803 cells treated with IL22 (100 μg/L). E, Western blotting detection of PD-L1 and XBP1s levels in XBP1- knockdown MGC-803 cells treated with IL22 and MGC-803 cells treated with IL22 or XBP1s inhibitor (STF083010, 30 μmol/L) in combination with IL22. F, The binding sequence of XBP1 on the CD274 promoter. G and H, ChIP ( G ) and luciferase reporter assay ( H ) showing the transcriptional regulation of CD274 by XBP1s under IL22 stimulation. I, Orthotopic gastric cancer mouse models ( n = 5 per group) were injected with anti-IL22 (200 μg per mouse), anti-CD90.2 antibody (150 μg per mouse), anti-CD90.2 antibody in combination with IL22 (500 ng per mouse), or anti-CD90.2 antibody in combination with XBP1s inhibitors (STF083010, 30 mg/kg) and IL22 for 2 weeks. IHC analysis was used to show IL22, XBP1s, and PD-L1 levels in gastric cancer tissues. Scale bar, 200 μm. J, Tumor volume of orthotopic gastric cancer models under treatments the same as in I . *, P < 0.05; **, P < 0.01; ***, P < 0.001; ns, nonsignificant.
    Genomics Xbp1s Mouse Fwd, supplied by Eurofins Genomics, used in various techniques. Bioz Stars score: 86/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
    https://www.bioz.com/product/xbp1s/fwd+genomics+mouse+xbp1s/pm42251995-331-213-222
    Average 86 stars, based on 1 article reviews
    genomics xbp1s mouse fwd - by Bioz Stars, 2026-09
    86/100 stars
    		  Buy from Supplier
    xbp1s  (Cell Signaling Technology Inc)
    86
    Cell Signaling Technology Inc xbp1s
    Sch B induced a dose-dependent increase in ROS levels in CCA cells. (A) BIP, (B) CHOP and (C) <t>XBP1s</t> expressions were determined by reverse-transcription quantitative PCR in CCA cells treated with different concentrations of Sch B (0, 10, 20, 40, 80, 160 µmol/l), (D) BIP, CHOP and XBP1s expression levels were determined by western blotting in CCA cells treated with different concentrations of Sch B (0, 40, 80, 160 µmol/l). (E) ROS levels in CCA cells treated with different concentrations of Sch B (0, 40, 80, 160 µmol/l) were measured using the ROS probe DCFH-DA. (F) Flow cytometry analysis of ROS levels in CCA cells following treatment with various Sch B concentrations (0, 40, 160 µmol/l). Statistical analysis was performed using ANOVA and Dunnett's post hoc test. *P<0.05, **P<0.01, ***P<0.001. CCA, cholangiocarcinoma; Sch B, Schisandrin B; Ctrl, control; ROS, reactive oxygen species.
    Xbp1s, supplied by Cell Signaling Technology Inc, used in various techniques. Bioz Stars score: 86/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
    https://www.bioz.com/product/xbp1s/pmc13051282-3-0-6
    Average 86 stars, based on 1 article reviews
    xbp1s - by Bioz Stars, 2026-09
    86/100 stars
    		  Buy from Supplier
    gene exp xbp1 hs02856596 m1  (Thermo Fisher)
    85
    Thermo Fisher gene exp xbp1 hs02856596 m1
    Sch B induced a dose-dependent increase in ROS levels in CCA cells. (A) BIP, (B) CHOP and (C) <t>XBP1s</t> expressions were determined by reverse-transcription quantitative PCR in CCA cells treated with different concentrations of Sch B (0, 10, 20, 40, 80, 160 µmol/l), (D) BIP, CHOP and XBP1s expression levels were determined by western blotting in CCA cells treated with different concentrations of Sch B (0, 40, 80, 160 µmol/l). (E) ROS levels in CCA cells treated with different concentrations of Sch B (0, 40, 80, 160 µmol/l) were measured using the ROS probe DCFH-DA. (F) Flow cytometry analysis of ROS levels in CCA cells following treatment with various Sch B concentrations (0, 40, 160 µmol/l). Statistical analysis was performed using ANOVA and Dunnett's post hoc test. *P<0.05, **P<0.01, ***P<0.001. CCA, cholangiocarcinoma; Sch B, Schisandrin B; Ctrl, control; ROS, reactive oxygen species.
    Gene Exp Xbp1 Hs02856596 M1, supplied by Thermo Fisher, used in various techniques. Bioz Stars score: 85/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
    https://www.bioz.com/product/xbp1s/Gene+Exp%2E+XBP1%2C+Hs02856596_m1/10__1042_slash_cs20250639-70-18-33
    Average 85 stars, based on 1 article reviews
    gene exp xbp1 hs02856596 m1 - by Bioz Stars, 2026-09
    85/100 stars
    		  Buy from Supplier
    toyocamycin xbp1 splicing inhibitor targetmol t17143  (TargetMol)
    94
    TargetMol toyocamycin xbp1 splicing inhibitor targetmol t17143
    Sch B induced a dose-dependent increase in ROS levels in CCA cells. (A) BIP, (B) CHOP and (C) <t>XBP1s</t> expressions were determined by reverse-transcription quantitative PCR in CCA cells treated with different concentrations of Sch B (0, 10, 20, 40, 80, 160 µmol/l), (D) BIP, CHOP and XBP1s expression levels were determined by western blotting in CCA cells treated with different concentrations of Sch B (0, 40, 80, 160 µmol/l). (E) ROS levels in CCA cells treated with different concentrations of Sch B (0, 40, 80, 160 µmol/l) were measured using the ROS probe DCFH-DA. (F) Flow cytometry analysis of ROS levels in CCA cells following treatment with various Sch B concentrations (0, 40, 160 µmol/l). Statistical analysis was performed using ANOVA and Dunnett's post hoc test. *P<0.05, **P<0.01, ***P<0.001. CCA, cholangiocarcinoma; Sch B, Schisandrin B; Ctrl, control; ROS, reactive oxygen species.
    Toyocamycin Xbp1 Splicing Inhibitor Targetmol T17143, supplied by TargetMol, used in various techniques. Bioz Stars score: 94/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
    https://www.bioz.com/product/xbp1s/Toyocamycin/pm41947198-748-120-124
    Average 94 stars, based on 1 article reviews
    toyocamycin xbp1 splicing inhibitor targetmol t17143 - by Bioz Stars, 2026-09
    94/100 stars
    		  Buy from Supplier
    rabbit anti xbp1 pb9463  (Boster Bio)
    93
    Boster Bio rabbit anti xbp1 pb9463
    Sch B induced a dose-dependent increase in ROS levels in CCA cells. (A) BIP, (B) CHOP and (C) <t>XBP1s</t> expressions were determined by reverse-transcription quantitative PCR in CCA cells treated with different concentrations of Sch B (0, 10, 20, 40, 80, 160 µmol/l), (D) BIP, CHOP and XBP1s expression levels were determined by western blotting in CCA cells treated with different concentrations of Sch B (0, 40, 80, 160 µmol/l). (E) ROS levels in CCA cells treated with different concentrations of Sch B (0, 40, 80, 160 µmol/l) were measured using the ROS probe DCFH-DA. (F) Flow cytometry analysis of ROS levels in CCA cells following treatment with various Sch B concentrations (0, 40, 160 µmol/l). Statistical analysis was performed using ANOVA and Dunnett's post hoc test. *P<0.05, **P<0.01, ***P<0.001. CCA, cholangiocarcinoma; Sch B, Schisandrin B; Ctrl, control; ROS, reactive oxygen species.
    Rabbit Anti Xbp1 Pb9463, supplied by Boster Bio, used in various techniques. Bioz Stars score: 93/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
    https://www.bioz.com/product/xbp1s/Anti-XBP1+Antibody+Picoband/bio_rxiv__64898__2026__04__01__715972-271-45-49
    Average 93 stars, based on 1 article reviews
    rabbit anti xbp1 pb9463 - by Bioz Stars, 2026-09
    93/100 stars
    		  Buy from Supplier
    xbp1s e9v3e rabbit monoclonal antibody  (Cell Signaling Technology Inc)
    86
    Cell Signaling Technology Inc xbp1s e9v3e rabbit monoclonal antibody
    Sch B induced a dose-dependent increase in ROS levels in CCA cells. (A) BIP, (B) CHOP and (C) <t>XBP1s</t> expressions were determined by reverse-transcription quantitative PCR in CCA cells treated with different concentrations of Sch B (0, 10, 20, 40, 80, 160 µmol/l), (D) BIP, CHOP and XBP1s expression levels were determined by western blotting in CCA cells treated with different concentrations of Sch B (0, 40, 80, 160 µmol/l). (E) ROS levels in CCA cells treated with different concentrations of Sch B (0, 40, 80, 160 µmol/l) were measured using the ROS probe DCFH-DA. (F) Flow cytometry analysis of ROS levels in CCA cells following treatment with various Sch B concentrations (0, 40, 160 µmol/l). Statistical analysis was performed using ANOVA and Dunnett's post hoc test. *P<0.05, **P<0.01, ***P<0.001. CCA, cholangiocarcinoma; Sch B, Schisandrin B; Ctrl, control; ROS, reactive oxygen species.
    Xbp1s E9v3e Rabbit Monoclonal Antibody, supplied by Cell Signaling Technology Inc, used in various techniques. Bioz Stars score: 86/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
    https://www.bioz.com/product/xbp1s/pm41946001-379-41-46
    Average 86 stars, based on 1 article reviews
    xbp1s e9v3e rabbit monoclonal antibody - by Bioz Stars, 2026-09
    86/100 stars
    		  Buy from Supplier

    Image Search Results


    IL22 upregulates PD-L1 expression in gastric cancer cells through the UPR IRE1α–XBP1 axis. A, mIF images show the alterations of PD-L1 + tumor cells (purple), CD4 + (green), and CD8 + (red) T cells in orthotopic gastric cancer tumors from control and Abhd16a -knockdown mice following IL22 treatment. Scale bar, 50 μm. B, KEGG pathway enrichment analysis of RNA-seq data of gastric cancer tissues with or without IL22 treatment. C, RT-PCR was used to assess the mRNA expression of key downstream molecules of the UPR branches ( XBP1 , ATF4 , ATF6 ) in control and IL22RA1 -knockdown gastric cancer cells. D, Western blotting analysis of PD-L1 and XBP1s levels in control and IL22RA1 -knockdown MGC-803 cells treated with IL22 (100 μg/L). E, Western blotting detection of PD-L1 and XBP1s levels in XBP1- knockdown MGC-803 cells treated with IL22 and MGC-803 cells treated with IL22 or XBP1s inhibitor (STF083010, 30 μmol/L) in combination with IL22. F, The binding sequence of XBP1 on the CD274 promoter. G and H, ChIP ( G ) and luciferase reporter assay ( H ) showing the transcriptional regulation of CD274 by XBP1s under IL22 stimulation. I, Orthotopic gastric cancer mouse models ( n = 5 per group) were injected with anti-IL22 (200 μg per mouse), anti-CD90.2 antibody (150 μg per mouse), anti-CD90.2 antibody in combination with IL22 (500 ng per mouse), or anti-CD90.2 antibody in combination with XBP1s inhibitors (STF083010, 30 mg/kg) and IL22 for 2 weeks. IHC analysis was used to show IL22, XBP1s, and PD-L1 levels in gastric cancer tissues. Scale bar, 200 μm. J, Tumor volume of orthotopic gastric cancer models under treatments the same as in I . *, P < 0.05; **, P < 0.01; ***, P < 0.001; ns, nonsignificant.

    Journal: Cancer Research

    Article Title: Nerves Stimulate Cross-talk Between Gastric Cancer and Group 3 Innate Lymphoid Cells to Enhance Immunosuppression

    doi: 10.1158/0008-5472.CAN-25-3092

    Figure Lengend Snippet: IL22 upregulates PD-L1 expression in gastric cancer cells through the UPR IRE1α–XBP1 axis. A, mIF images show the alterations of PD-L1 + tumor cells (purple), CD4 + (green), and CD8 + (red) T cells in orthotopic gastric cancer tumors from control and Abhd16a -knockdown mice following IL22 treatment. Scale bar, 50 μm. B, KEGG pathway enrichment analysis of RNA-seq data of gastric cancer tissues with or without IL22 treatment. C, RT-PCR was used to assess the mRNA expression of key downstream molecules of the UPR branches ( XBP1 , ATF4 , ATF6 ) in control and IL22RA1 -knockdown gastric cancer cells. D, Western blotting analysis of PD-L1 and XBP1s levels in control and IL22RA1 -knockdown MGC-803 cells treated with IL22 (100 μg/L). E, Western blotting detection of PD-L1 and XBP1s levels in XBP1- knockdown MGC-803 cells treated with IL22 and MGC-803 cells treated with IL22 or XBP1s inhibitor (STF083010, 30 μmol/L) in combination with IL22. F, The binding sequence of XBP1 on the CD274 promoter. G and H, ChIP ( G ) and luciferase reporter assay ( H ) showing the transcriptional regulation of CD274 by XBP1s under IL22 stimulation. I, Orthotopic gastric cancer mouse models ( n = 5 per group) were injected with anti-IL22 (200 μg per mouse), anti-CD90.2 antibody (150 μg per mouse), anti-CD90.2 antibody in combination with IL22 (500 ng per mouse), or anti-CD90.2 antibody in combination with XBP1s inhibitors (STF083010, 30 mg/kg) and IL22 for 2 weeks. IHC analysis was used to show IL22, XBP1s, and PD-L1 levels in gastric cancer tissues. Scale bar, 200 μm. J, Tumor volume of orthotopic gastric cancer models under treatments the same as in I . *, P < 0.05; **, P < 0.01; ***, P < 0.001; ns, nonsignificant.

    Article Snippet: For the animal experiment, LysoPS (2.5 mg/kg, Sigma, 858144P), GPR34 inhibitor (GPR34 receptor antagonist 2, 20 mg/kg, MERYER, 907952), AKT inhibitor (perifosine, 20 mg/kg, MedChemExpress, HY-50909), XBP1s inhibitor (STF-083010, 30 mg/kg, MedChemExpress, HY-15845), IL22 Monoclonal Antibody (200 μg/mouse, eBioscience, 16-7222-82, RRID: AB_2016695), rmIL22 (500 ng/mouse, ABclonal, RP02942), and CD90.2 (150 μg/mouse, BioXCell, BE0066, RRID: AB_1107682) for ILC3 depletion were intraperitoneally injected once every 3 days.

    Techniques: Expressing, Control, Knockdown, RNA Sequencing, Reverse Transcription Polymerase Chain Reaction, Western Blot, Binding Assay, Sequencing, Luciferase, Reporter Assay, Injection

    Combination therapy enhances the anti–PD-L1 immunotherapeutic effect in gastric cancer. A and B, After tumor formation, the orthotopic gastric cancer mice ( n = 5 per group) were treated with anti–PD-L1 (100 μg per mouse), GPR34 inhibitor (20 mg/kg), or XBP1s inhibitor (30 mg/kg) every 3 days or ACh inhibitor (2.5 mg/kg) daily. Combinations of anti–PD-L1 with each inhibitor followed the every 3-day dosing schedule for a total duration of 2 weeks via i.p. injection. Living images were used to monitor tumor progression at 5-day intervals from the time of drug administration ( A ); IHC and mIF were performed to detect PD-L1 and XBP1s levels and proportions of CD4 + (green) and CD8 + (red) T cells in gastric cancer tissues at the end of treatments ( B ). Scale bars, 1.000e+5 –∼ 5.000e + 5 p/s/cm 2 /sr for living images; 200 μm for IHC; 50 μm for immunofluorescence. C and D, Representative images ( C ) and tumor volume ( D ) of subcutaneous tumors. The administration protocol for the mice was consistent with the description provided in A and B . **, P < 0.01; ***, P < 0.001.

    Journal: Cancer Research

    Article Title: Nerves Stimulate Cross-talk Between Gastric Cancer and Group 3 Innate Lymphoid Cells to Enhance Immunosuppression

    doi: 10.1158/0008-5472.CAN-25-3092

    Figure Lengend Snippet: Combination therapy enhances the anti–PD-L1 immunotherapeutic effect in gastric cancer. A and B, After tumor formation, the orthotopic gastric cancer mice ( n = 5 per group) were treated with anti–PD-L1 (100 μg per mouse), GPR34 inhibitor (20 mg/kg), or XBP1s inhibitor (30 mg/kg) every 3 days or ACh inhibitor (2.5 mg/kg) daily. Combinations of anti–PD-L1 with each inhibitor followed the every 3-day dosing schedule for a total duration of 2 weeks via i.p. injection. Living images were used to monitor tumor progression at 5-day intervals from the time of drug administration ( A ); IHC and mIF were performed to detect PD-L1 and XBP1s levels and proportions of CD4 + (green) and CD8 + (red) T cells in gastric cancer tissues at the end of treatments ( B ). Scale bars, 1.000e+5 –∼ 5.000e + 5 p/s/cm 2 /sr for living images; 200 μm for IHC; 50 μm for immunofluorescence. C and D, Representative images ( C ) and tumor volume ( D ) of subcutaneous tumors. The administration protocol for the mice was consistent with the description provided in A and B . **, P < 0.01; ***, P < 0.001.

    Article Snippet: For the animal experiment, LysoPS (2.5 mg/kg, Sigma, 858144P), GPR34 inhibitor (GPR34 receptor antagonist 2, 20 mg/kg, MERYER, 907952), AKT inhibitor (perifosine, 20 mg/kg, MedChemExpress, HY-50909), XBP1s inhibitor (STF-083010, 30 mg/kg, MedChemExpress, HY-15845), IL22 Monoclonal Antibody (200 μg/mouse, eBioscience, 16-7222-82, RRID: AB_2016695), rmIL22 (500 ng/mouse, ABclonal, RP02942), and CD90.2 (150 μg/mouse, BioXCell, BE0066, RRID: AB_1107682) for ILC3 depletion were intraperitoneally injected once every 3 days.

    Techniques: Injection, Immunofluorescence

    Sch B induced a dose-dependent increase in ROS levels in CCA cells. (A) BIP, (B) CHOP and (C) XBP1s expressions were determined by reverse-transcription quantitative PCR in CCA cells treated with different concentrations of Sch B (0, 10, 20, 40, 80, 160 µmol/l), (D) BIP, CHOP and XBP1s expression levels were determined by western blotting in CCA cells treated with different concentrations of Sch B (0, 40, 80, 160 µmol/l). (E) ROS levels in CCA cells treated with different concentrations of Sch B (0, 40, 80, 160 µmol/l) were measured using the ROS probe DCFH-DA. (F) Flow cytometry analysis of ROS levels in CCA cells following treatment with various Sch B concentrations (0, 40, 160 µmol/l). Statistical analysis was performed using ANOVA and Dunnett's post hoc test. *P<0.05, **P<0.01, ***P<0.001. CCA, cholangiocarcinoma; Sch B, Schisandrin B; Ctrl, control; ROS, reactive oxygen species.

    Journal: Oncology Letters

    Article Title: Schisandrin B suppresses cholangiocarcinoma by targeting the ROS/p38 MAPK/NF-κB axis

    doi: 10.3892/ol.2026.15551

    Figure Lengend Snippet: Sch B induced a dose-dependent increase in ROS levels in CCA cells. (A) BIP, (B) CHOP and (C) XBP1s expressions were determined by reverse-transcription quantitative PCR in CCA cells treated with different concentrations of Sch B (0, 10, 20, 40, 80, 160 µmol/l), (D) BIP, CHOP and XBP1s expression levels were determined by western blotting in CCA cells treated with different concentrations of Sch B (0, 40, 80, 160 µmol/l). (E) ROS levels in CCA cells treated with different concentrations of Sch B (0, 40, 80, 160 µmol/l) were measured using the ROS probe DCFH-DA. (F) Flow cytometry analysis of ROS levels in CCA cells following treatment with various Sch B concentrations (0, 40, 160 µmol/l). Statistical analysis was performed using ANOVA and Dunnett's post hoc test. *P<0.05, **P<0.01, ***P<0.001. CCA, cholangiocarcinoma; Sch B, Schisandrin B; Ctrl, control; ROS, reactive oxygen species.

    Article Snippet: XBP1s , 12782 , 1:1,000 , Cell Signaling Technology, Inc..

    Techniques: Reverse Transcription, Real-time Polymerase Chain Reaction, Expressing, Western Blot, Flow Cytometry, Control

    NAC counteracted the upregulatory effect of Sch B on ROS expression. After treatment with 160 µmol/l Sch B + different concentrations of NAC (0, 0.5, 1, 3, 6 µmol/l). BIP, CHOP and XBP1s expression determined by (A) western blotting and (B) reverse transcription-quantitative PCR in CCA cells. (C) LDH activity in cell culture medium. (D) Cell activity levels detected by the Calcein AM-PI live cell staining. (E) Western blot analysis of the expression levels of Bax in CCA cells. Statistical analysis was performed using ANOVA and Dunnett's post hoc test. **P<0.01, ***P<0.001. ROS, reactive oxygen species; CCA, cholangiocarcinoma; NAC, N-acetyl-L-cysteine; ctrl, control; Sch B, Schisandrin B; LDH, lactate dehydrogenase.

    Journal: Oncology Letters

    Article Title: Schisandrin B suppresses cholangiocarcinoma by targeting the ROS/p38 MAPK/NF-κB axis

    doi: 10.3892/ol.2026.15551

    Figure Lengend Snippet: NAC counteracted the upregulatory effect of Sch B on ROS expression. After treatment with 160 µmol/l Sch B + different concentrations of NAC (0, 0.5, 1, 3, 6 µmol/l). BIP, CHOP and XBP1s expression determined by (A) western blotting and (B) reverse transcription-quantitative PCR in CCA cells. (C) LDH activity in cell culture medium. (D) Cell activity levels detected by the Calcein AM-PI live cell staining. (E) Western blot analysis of the expression levels of Bax in CCA cells. Statistical analysis was performed using ANOVA and Dunnett's post hoc test. **P<0.01, ***P<0.001. ROS, reactive oxygen species; CCA, cholangiocarcinoma; NAC, N-acetyl-L-cysteine; ctrl, control; Sch B, Schisandrin B; LDH, lactate dehydrogenase.

    Article Snippet: XBP1s , 12782 , 1:1,000 , Cell Signaling Technology, Inc..

    Techniques: Expressing, Western Blot, Reverse Transcription, Real-time Polymerase Chain Reaction, Activity Assay, Cell Culture, Staining, Control